DR-223 Identification of Mutations in Signaling Proteins in Metastatic Breast Cancer Cells
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-223 Identification of Mutations in Signaling Proteins in Metastatic Breast Cancer Cells
Cancer-related signaling pathways frequently involve protein kinase C (PKC), a prominent enzyme that phosphorylates alpha-tubulin, a building block of microtubules. …
DR-218 Large-scale analysis of non-coding alterations in endocrine therapy resistance of breast cancer
Breast cancer is the second leading cause of cancer-related death in women worldwide. Hormone therapy has been proven effective to …
DR-215 Interplay between drug treatment and rearrangment occurrence
Cancer is driven by mutations in the genome. Several drugs, including some of the most widely used compound types, induce …
DR-204 Drivers of therapy resistance in cancer of the head and neck
Head and neck cancer can be cured in approximately half of patients suitable for radical treatment with radiotherapy. Treatment failures …
DR-185 A human interpreter validation on results generated by artificial intelligence (AI) algorithms developed for outcome and response predictions for CRC and melanoma patients: optimal use and validation of multi-layer research data
We want to achieve better care for patients with CRC and melanoma, by allowing a multidisciplinary team of researchers to …
DR-275 Identification of somatic mutations in non-coding regions including 5’UTR, 3’UTRs, and microRNAs
Thousands of cancer-driving mutations have been detected in the cancer genome. Some of them are used as cancer biomarkers or …
DR-273 Tackling primary and acquired resistance to PD-(L)1 checkpoint inhibition in advanced non-small cell lung cancer
In recent years the treatment of patients with lung cancer has improved tremendously with the introduction of immunotherapy. This therapy …
DR-270 Therapy resistance mechamisms in uterine cancers
This project will focus on treatment resistance mechanisms in uterine cancers to develop novel targeted treatments as adjuvants or combination …
DR-266 Tumor genotype and the risk of cancer-associated venous thromboembolism: results from 4000 cancer biopsies (PANDORA study)
Venous thromboembolism (VTE), a venous blood clot, frequently occurs in cancer patients, and substantially affects morbidity, quality of life, and …
DR-265 Identification of extrachromosomal DNA-driven Mutational Processes Operating in Tumor Metastasis
Summary = Previous efforts in cancer research have been dedicated to identifying genetic alterations on the linear form of DNA, …
DR-263 Whole-genome mutational patterns
Mutations are generated by endogenous (replication errors) and exogenous processes (UV light). Studying the mutational patterns observed across both genes …
DR-260 Variation in mutational processes across the human genome
Cancer is a disease of the genome. Random factors, environmental exposures and also certain biological mechanisms have the potential to …
Deze complete DNA-test maakt de individuele behandeling mogelijk en beperkt daarmee onwenselijke bijwerkingen.